To Be Discontinued Injection Oncology

Irinotecan Hydrochloride Inj · 403 days since initial FDA posting

Brand: IRINOTECAN HYDROCHLORIDE

FDA lists Irinotecan Hydrochloride Inj as To Be Discontinued (Teva Pharmaceuticals USA, Inc.).

No availability text on this FDA row.

Irinotecan Hydrochloride Injection: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Irinotecan Hydrochloride Injection
Manufacturer
Teva Pharmaceuticals USA, Inc.
Dosage Form
Injection
Presentation
Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)
Package NDC
45963-614-55

Status & Timeline

Status
To Be Discontinued
First Reported
Aug 4, 2025
Last Updated
Aug 4, 2025
Therapeutic Category
Oncology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Product not anticipated to be available beyond mid-late September 2025

Nearby, Other Irinotecan Shortage Records

Irinotecan Hydrochloride Injection

Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Teva Pharmaceuticals USA, Inc.

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Ingenus Pharmaceuticals LLC

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Ingenus Pharmaceuticals LLC

Injection

To Be Discontinued

FDA reason on file: Product not anticipated to be available beyond mid-late September 2025. General shortage guidance lives on the tracker hub.

← All Drug Shortages